# Trading Analysis — 2026-09-10

## Portfolio Snapshot

| Metric | Value |
|---|---|
| **Total Value** | €9,844.84 |
| **Daily Change** | -56.80€ (-0.57%) |
| **Total Return (since inception)** | -1.55% |
| **Cash** | €2,690.46 (27.33%) |
| **Open Positions** | 8 |
| **Realized P&L** | €-363.13 |
| **Unrealized P&L** | €+46.74 |

**Benchmark (equal-weight, 32 assets):** €10,071.97 (+0.72%) — strategy trails by -2.27 pp on the full period.

## Risk Metrics

| Metric | Value |
|---|---|
| Sharpe Ratio | -0.50 |
| Sortino Ratio | -0.78 |
| Volatility (annualized) | 5.01% |
| Max Drawdown | -1.55% |
| CVaR 95% | +0.76% |
| VaR 95% | +0.72% |

## Today's Decision — All HOLD (0 trades)

**Trades executed: 0.** Sixth consecutive full-hold session. The LLM kept the neutral-regime posture: mean reversion and trend-following stay disabled, cash sits at 27.3% inside the 15–30% NORMAL-band, and no position breached the -5% stop-loss (worst is TLT at -3.79%). Several names (FEZ, REET, SAN.PA, IJR) print RSI < 30, but buying them would violate the disabled mean-reversion directive. PDBC is overbought (RSI 78, Bollinger 1.10) but does not strictly clear the 1.1 confirmation threshold — the winner keeps running.

### LLM Reasoning (excerpt)

> Current cash level is ~27.3%, which sits comfortably within the 15-30% target range for a NORMAL volatility regime, meaning capital is not being dragged and no forced deployment is required. The market regime analysis indicates a neutral trend with both mean reversion and trend following strategies currently disabled. While several assets (FEZ, REET, SAN.PA, IJR) are technically oversold (RSI < 30), buying them would violate the disabled mean reversion directive. PDBC is overbought (RSI 78, BB 1.10) but does not strictly meet the >1.1 Bollinger threshold for a confirmed technical reversal, and letting the winner run aligns with our sell discipline. No single position has breached the -5% stop-loss threshold, and total portfolio drawdown is a manageable -1.55%. Applying a CVaR mindset and loss aversion, preserving capital and maintaining current diversified exposure without forcing trades in a neutral regime is the optimal risk-adjusted decision.

## Open Positions

| Ticker | Value | Weight | Unrealized P&L |
|---|---|---|---|
| SPY | €2,010.14 | 20.42% | +1.51% |
| OR.PA | €1,335.44 | 13.56% | +1.47% |
| FEZ | €1,293.47 | 13.14% | +0.73% |
| IJR | €854.82 | 8.68% | -3.63% |
| TLT | €524.13 | 5.32% | -3.79% |
| PDBC | €509.37 | 5.17% | +12.45% |
| REET | €445.96 | 4.53% | -3.69% |
| SAN.PA | €181.05 | 1.84% | +0.93% |

## Weekly Summary — 2026-W37

| Metric | Value |
|---|---|
| Week Start Value | €9,960.06 |
| Week End Value | — |
| Weekly Change | — |
| Sessions | 4 (week finalizes Friday) |

## Risk Management Notes

- Weekly trade count: **0/4** used.
- **PDBC watch:** RSI 78, Bollinger Position 1.10 — right at the profit-take confirmation boundary; Friday's close will decide whether the threshold strictly clears.
- Worst performers: TLT -3.79%, REET -3.69%, IJR -3.63% — all still above the -5% stop-loss, but the cluster of oversold small-cap / rate-sensitive names is worth monitoring.
- Largest exposure SPY at ~20.4% of portfolio, below the 25% concentration cap.
- Drawdown deepened to -1.55% as the strategy trails a mildly positive tape; the capital-preservation posture in a neutral regime is unchanged.
- Note: the equal-weight benchmark turned positive (+0.72%) while the strategy sits at -1.55%, so the full-period gap widened to -2.27 pp — a rising tape is the hardest environment for a high-cash, trade-disciplined book.

## Research Session Notes — 2026-09-10 (evening)

Analysis suite re-run after today's all-HOLD daily run (4th session of W37):

- **Decision quality (30d):** only 4 decision days with trades in the forward window; 1D win rate 50.0% (Buy 75.0%, Sell 0.0%), decision Sharpe -0.349 — sample still too small for significance.
- **Behavioral:** error rate 0% since 2026-08-01 (10/90 historically, concentrated Mar–Jun). Churn: 34 round trips, 26.5% win rate, avg hold 32.1 days; long holds (>14d) win 41.2% vs 0% for short (≤3d) — patience remains the edge.
- **Cash drag:** 101 days analyzed — 63.4% above target (64 days, 54 with cap headroom vs 10 cap-binding). Cash 27.3%, inside the NORMAL 15–30% band; drag diagnosis unchanged: prompt is not deploying, not the cap.
- **Benchmark:** alpha vs SPY buy-and-hold since 2026-02-17: **-13.79 pp** (Strategy -1.55% | SPY +12.24%). High-cash book lags a rising tape — the widest full-period gap of the current hold streak.
- Full-period equal-weight benchmark gap: -2.27 pp (benchmark +0.72% vs strategy -1.55%).
- 1,129 tests pass; all analysis artifacts regenerated for 2026-09-10.

*Almost surely, patience pays.* 🦀
